Our Approach to Ribosome targeted drugs
Many drug classes are known to bind to all or part of the ribosome. However, many of these drugs have safety, efficacy or delivery liabilities that have prevented their full potential to be tapped
At Zikani, we start with a rational approach to designing Ribosome Targeting Molecules (RTMs), that expands the structural diversity of these molecules. Our goal is to develop breakthrough RTMs that are orally delivered, safe and potent for the most difficult diseases.
We have created a potent library of over 2000 RTMs using this fully synthetic medicinal chemistry platform with a broad range of physio-chemical properties and functional activity. These compounds share a conserved binding site to the large ribosomal sub unit, which enables them to be applied in diverse therapeutic applications, such as anti-inflammatory, oncology and infectious diseases.
Our platform, published in Nature in 2016, allows for the synthesis of novel ribosome targeting compounds from basic chemical building blocks.
Join the Zikani Team
Make a difference, and make it soon. Our groundbreaking technology provides the opportunity for rapid development of important new drugs. Come join a highly motivated and focused team.
- Seiple IB et al. A platform for the discovery of new macrolide antibiotics. Nature. 2016 May 19;533(7603):338-45. Pubmed.
- Lahiri SD and Alm RA. Improved Antimicrobial Activity of Fully Synthetic Macrolides against Macrolide Resistant Gram-positive Isolates. Poster presented at: ASM Microbe; June 19, 2016; Boston, MA. Link.